- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01775475
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa
Study Overview
Status
Conditions
- AIDS-related Peripheral/Systemic Lymphoma
- AIDS-related Diffuse Large Cell Lymphoma
- AIDS-related Diffuse Mixed Cell Lymphoma
- AIDS-related Diffuse Small Cleaved Cell Lymphoma
- AIDS-related Immunoblastic Large Cell Lymphoma
- AIDS-related Lymphoblastic Lymphoma
- AIDS-related Small Noncleaved Cell Lymphoma
- Stage III AIDS-related Lymphoma
- Stage IV AIDS-related Lymphoma
Detailed Description
PRIMARY OBJECTIVES:
I. To compare the efficacy of standard cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) and an oral chemotherapy regimen for acquired immune deficiency syndrome (AIDS)-related (AR)-non-Hodgkin lymphoma (NHL) in sub-Saharan Africa with respect to overall survival (OS).
SECONDARY OBJECTIVES:
I. To compare the objectives response rate (ORR) of persons randomized to CHOP and oral chemotherapy.
II. To compare the progression free survival (PFS) of persons randomized to CHOP and oral chemotherapy.
III. To compare the safety and tolerance of persons randomized to CHOP and oral chemotherapy.
TERTIARY OBJECTIVES:
I. To describe the rates of completion of therapy of persons randomized to CHOP and oral chemotherapy.
II. To describe adherence to chemotherapy of persons randomized to CHOP and oral chemotherapy.
III. To describe adherence to antiretroviral therapy of persons randomized to CHOP and oral chemotherapy.
IV. To describe the effects of therapy on HIV control, as measured by cluster of differentiation (CD)4 counts and HIV viral load.
V. To investigate correlates of survival.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive CHOP chemotherapy comprising cyclophosphamide intravenously (IV) on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone orally (PO) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive lomustine PO once daily (QD) on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 3, 6, 12, 18, and 24 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to understand and the willingness to provide written informed consent to participate
- Adults, 18 years of age or older; date of birth should be determined based on the best possible information or source documentation available
HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or confirmed by HIV-1 antigen or plasma HIV-1 ribonucleic acid (RNA) viral load > 1,000 copies/mL
- NOTE: the term "licensed" refers to a United States (U.S.) Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally
- WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load
- Biopsy-proven, measurable or assessable systemic NHL that has been confirmed by an AIDS Malignancy Clinical Trial Consortium (AMC)-approved site pathologist; if a hard copy of the pathology report is unavailable at the time of enrollment, a verbal report by the pathologist confirming the diagnosis must be documented in the medical chart
- Pathology slides from tumor tissue obtained by surgical excision or core biopsy must be reviewed by the designated site pathologist, or backup pathologist, prior to study entry; confirmation of the diagnosis must be documented by the AMC-approved pathologist prior to study entry; please reference the AMC-068 Manual of Procedures (MOP) for further instructions on documenting the diagnosis; the site pathologist for NHL must be approved through the AMC's external quality assessment (EQA) process
- Participants must have fifteen blank(unstained) slides or a diagnostic tissue block must be available for central pathology review by the AMC Core Pathology Laboratory
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
- Participants must have an estimated life expectancy of > 6 weeks
- White blood cells (WBC) >= 3,000 cells/uL (3.0 x 10^9 L) or
- Absolute granulocytes >= 1500 cells/uL (1.5 x 10^9 L)
- Platelets >= 100,000 cells/uL (75 x 10^9 L)
- Hemoglobin > 8 g/dL (5.0 mmol/L)
- Patients may enroll with lower hematologic values, if bone marrow involvement is documented; in this case, patients should be transfused to hemoglobin > 8 g/dL
- Serum creatinine < 3.0 mg/dL (265.2 umol/L)
- Total bilirubin =< 1.5 institutional upper limit of normal (ULN), unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications (e.g., indinavir, tenofovir, or atazanavir); if secondary to lymphomatous involvement, an initial upper limit of total bilirubin 5 mg/dL (85.5 uM/L) should be utilized - for direct bilirubin > 1.2 mg/dL (20.5 uM/L)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 institutional ULN (unless elevated secondary to lymphomatous involvement of the liver)
- Participants must have a lumbar puncture with negative cerebral spinal fluid cytology within 6 weeks prior to enrollment; participants must be without evidence for central nervous system (CNS) lymphoma on neurological exam and have no radiographic evidence (if radiographic studies are done) of CNS lymphoma (inclusive of parenchymal, vitreal, or leptomeningeal involvement)
- Participants must not have had any prior chemotherapy or radiation therapy and no more than 10 days of corticosteroids in the preceding 30 days prior to enrollment
- All participants must be prescribed combination antiretroviral therapy with the goal of virological suppression using an acceptable regimen that adheres to national guidelines for treatment of HIV infection; non-suppressed, treatment experienced patients, defined as patients with a viral load > 400 copies/mL who have been on antiretroviral therapy for more than 4 months can be enrolled if an alternative antiretroviral therapy (ART) regimen is available that includes at least two ART drugs that, in the opinion of the site investigator, are expected to have activity based on genotypic testing (if available) and treatment history; patients are not allowed to receive zidovudine (azidothymidine [AZT]) as part of concurrent chemotherapy and ART regimen, since it is myelosuppressive; zidovudine may be discontinued and substituted as clinically indicated prior to or at the time of enrollment.
- Participants of childbearing potential, defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months), must have a pregnancy test within 7 days prior to enrollment and agree to use an effective form of contraception (e.g., barrier contraception, highly effective hormonal contraception)
- Participants are allowed to have an active infection(s) for which they are receiving drug treatment provided the clinical status is judged to be stable and survival is estimated to be at least 6 weeks
- Participants must, in the opinion of the investigatory, be capable of complying with the protocol
- Participants must be able to take oral medications
- Participants must have a CD4 count performed within 30 days of enrollment
Exclusion Criteria:
- Inability to provide informed consent
- A medical or psychiatric illness that precludes ability to give informed consent or is likely to interfere with the ability to comply with the protocol stipulations
- Participants with circumstances that will not permit completion of the study or required follow-up; for instance, if travel to and from treatment site is an issue
- Pregnant or breastfeeding
- Inability to swallow oral medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (CHOP)
Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5.
Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given PO
Other Names:
Given PO
Other Names:
|
Experimental: Arm II (oral chemotherapy)
Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26.
Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given IV
Other Names:
Given PO
Other Names:
Given PO
Other Names:
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Up to 24 months
|
Proportion of participants who survived 2 years
|
Up to 24 months
|
Overall Response Rate
Time Frame: Up to 24 months
|
Overall response is complete or partial response as defined by response definitions of the 2014 International Conference on Malignant Lymphoma Imaging Working Group (i.e.
Lugano classification).
Complete response is the disappearance of all lesions with no new lesions detected.
Partial response is >=50% decrease in the sum of the perpendicular diameters of up to 6 target measurable nodes and extranodal sites and no new sites of disease.
|
Up to 24 months
|
Progression-free Survival
Time Frame: Up to 24 months
|
Proportion of participants who survived without disease progression at 2 years
|
Up to 24 months
|
Participants Who Experienced an Adverse Event
Time Frame: Up to 24 months
|
Number of participants who experienced an adverse event
|
Up to 24 months
|
Number of Patients Who Complete Treatment
Time Frame: Up to 18 weeks
|
Number of patients who complete chemotherapy treatment.
|
Up to 18 weeks
|
Proportion of Patients Who Are Adherent to Antiretroviral Therapy
Time Frame: Up to 24 months
|
Number of patients who did not miss any of their doses of antiretroviral therapy
|
Up to 24 months
|
Proportion of Patients Who Are Adherent to Chemotherapy
Time Frame: Up to 18 weeks
|
Patients who did not miss any doses of chemotherapy
|
Up to 18 weeks
|
Change in Absolute CD4 Count From Baseline to Post-treatment
Time Frame: From baseline to 18 weeks
|
Change in absolute CD4 count from baseline to post-treatment (visit 6)
|
From baseline to 18 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert Strother, AIDS Associated Malignancies Clinical Trials Consortium
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia, Lymphoid
- Leukemia
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, Large-Cell, Immunoblastic
- Plasmablastic Lymphoma
- Lymphoma, AIDS-Related
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Etoposide
- Etoposide phosphate
- Prednisone
- Doxorubicin
- Liposomal doxorubicin
- Vincristine
- Lomustine
- Procarbazine
Other Study ID Numbers
- AMC-068
- U01CA121947 (U.S. NIH Grant/Contract)
- NCI-2012-01695 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AIDS-related Peripheral/Systemic Lymphoma
-
National Cancer Institute (NCI)CompletedBryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related LymphomaAIDS-related Peripheral/Systemic Lymphoma | AIDS-related Diffuse Large Cell Lymphoma | AIDS-related Diffuse Mixed Cell Lymphoma | AIDS-related Small Noncleaved Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAIDS-related Peripheral/Systemic Lymphoma | AIDS-related Diffuse Large Cell Lymphoma | AIDS-related Immunoblastic Large Cell Lymphoma | AIDS-related Small Noncleaved Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAIDS Related Lymphoma | AIDS-Associated LymphomaUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Medulloblastoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Leptomeningeal Metastases | Childhood Diffuse Large Cell Lymphoma | Childhood Immunoblastic Large Cell Lymphoma and other conditionsUnited States
-
Rotkreuzklinikum München gGmbHRecruitingAIDS Related Lymphoma | HIV Related LymphomaGermany, Spain, United Kingdom, Netherlands
-
He HuangRecruitingAIDS Related Lymphoma and LympholeukemiaChina
-
Fondation Ophtalmologique Adolphe de RothschildCompletedAIDS Related Lymphoma | Central Nervous System LymphomaFrance
-
French National Agency for Research on AIDS and...Hoffmann-La RocheTerminated
-
National Cancer Institute (NCI)TerminatedPost-transplant Lymphoproliferative Disorder | Recurrent Childhood Large Cell Lymphoma | Recurrent Childhood Lymphoblastic Lymphoma | Recurrent Childhood Small Noncleaved Cell Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | AIDS-related Peripheral/Systemic Lymphoma | AIDS-related...United States
-
Universitätsklinikum Hamburg-EppendorfTerminatedHIV Infections | AIDS-related LymphomaGermany
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States